| monrd0024 | |
| Medals oligonucleic drug ID | monrd0024 |
| ATC Classification | S01LA03 |
| Product Name | Macugen |
| Synonims | Pegaptanib |
| Country | Germany US |
| Company | Society (Institute) for clinical research (OSI) Eyetech, Inc |
| phase | AD |
| Type | Aptamer |
| Adaptation Diseases | Wet Macular Degeneration neovascular age-related macular degeneration |
| Target Molecule | VEGF |
| Remarks | Macugen is used for the treatment of angiogenic age-related macular degeneration (AMD). |
| Nucleic Acid Sequence | ((2'-deoxy-2'-fluoro)C-Gm-Gm-A-A-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-Am-Gm-(2'-deoxy-2'-fluoro)U-Gm-Am-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'fluoro)U-Am-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)U-(2'deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Gm-(3'→3')-dT), 5'-ester with α,α'-[4,12-dioxo-6[[[5-(phosphoonoxy)pentyl]amino] carbonyl]-3,13-dioxa-5,11-diaza-1,15pentadecanediyl]bis[ω-methoxypoly(oxy-1,2-ethanediyl)] |
| Source | http://www.rxlist.com/macugen-drug.htm, http://www.kegg.jp/dbget-bin/www_bget?D05386, https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-006290-90/DE, https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-000722-31/DE |
| DrugBank | DB04895 |
| TargetProtein - UniProt | P15692 |
| TargetProtein - PDB | 3BDY |